Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
4 Profitable Companies With Solid Financial Conditions
12:52pm, Friday, 27'th May 2022
When screening the market for value opportunities, investors may want to consider stocks that represent companies with high profitability and robust financial conditions. The companies below meet thes
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
07:42am, Thursday, 26'th May 2022
New treatments will step in to replace blockbuster eye medication EYLEA.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
03:16am, Wednesday, 25'th May 2022
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Regeneron's (REGN) Evkeeza Positive in Late-Stage Study
01:33pm, Monday, 23'rd May 2022
Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
12:03pm, Monday, 23'rd May 2022
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Regeneron: Bright Future Ahead
03:55am, Monday, 23'rd May 2022
Regeneron has a very strong pipeline consisting of treatments that can complement current cash cows (EYLEA and Dupixent) along with potential blockbusters. Even if EYLEA rapidly loses market share aft
Regeneron's Growth Set To Slow, But Could Outperform Downbeat Consensus Forecasts
09:12pm, Friday, 20'th May 2022
Regeneron just posted another impressive quarter for earnings (+16% YoY) and revenues (+17% YoY). Growth is set to slow after a one-time boost from its COVID antibody cocktail last year and an upcomin
My 'Do Nothing Club' Returned 68% in the Past Year
10:35am, Monday, 16'th May 2022
Certain predators can't see their prey if the prey holds still.
Is Regeneron In Trouble After Sales Declined 40% In a Single Quarter?
09:05am, Thursday, 12'th May 2022
The pharmaceutical company's COVID-19 treatment wasn't the only product suffering this past quarter.
How Biotech Company Regeneron Flipped The Script In Drug Development
06:15pm, Monday, 09'th May 2022
It's hard to imagine Regeneron Pharmaceuticals as anything but a powerhouse in drug development, but Chief Financial Officer Robert Landry recalls a different time for his company and the rest of the
Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected
01:32pm, Wednesday, 04'th May 2022
Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.
Regeneron Pharmaceuticals (REGN) CEO, Leonard Schleifer on Q1 2022 Results - Earnings Call Transcript
01:32pm, Wednesday, 04'th May 2022
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - P
Regeneron Posts Drop In Q1 Profit As COVID Antibody Sales Hit, Shares Fall
09:59am, Wednesday, 04'th May 2022
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $11.49 per share for Q1 FY22, up 16% Y/Y, beating the $10.04 estimate. Sales increased 17% to $2.96 billion, surpassing the analysts' consensus
Regeneron (REGN) Q1 Earnings and Revenues Beat Estimates
09:02am, Wednesday, 04'th May 2022
Regeneron (REGN) delivered earnings and revenue surprises of 22.63% and 9.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron Stock Rises as First-Quarter Earnings Top Forecasts
07:16am, Wednesday, 04'th May 2022
The pharmaceutical company posts first-quarter revenue of $2.97 billion, up 17% from a year earlier.
